JBIO
Jade Biosciences, Inc.Company Information
- Company Name
- Jade Biosciences, Inc.
- CIK
- CIK0001798749
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- JBIO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- JBIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-16
- Last sale
- 2024-06-14
- Shares purchased (TTM)
- 934,110
- Shares sold (TTM)
- 45,600
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 72,709,700
- Shares outstanding
- 61,050,775
- Ownership
- 119.10%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -8.42%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 107 | 55 | 88 | 50 | 221 | 44 | 69 | 31 | 31 | 9 | 23 | 32 | ||||||
| Short Term Investments | 354 | 256 | 248 | 149 | - | 32 | 0 | 58 | 73 | 90 | 99 | 103 | ||||||
| Prepaid Expense And Other Assets Current | 10 | 7 | 13 | 2 | 2 | 1 | 0 | 2 | 7 | 4 | 2 | 2 | ||||||
| Assets Current | 471 | 319 | 349 | 201 | 223 | 77 | 70 | 91 | 111 | 103 | 124 | 138 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | - | 3 | 0 | 0 | 3 | 2 | 2 | ||||||
| Assets | 472 | 319 | 350 | 202 | 224 | 78 | 73 | 91 | 112 | 107 | 127 | 141 | ||||||
Liabilities Current | ||||||||||||||||||
| Operating Lease Liability Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable Current | 7 | 4 | 2 | 1 | 8 | 0 | 1 | 1 | 4 | 3 | 2 | 4 | ||||||
| Liabilities Current | 32 | 22 | 17 | 22 | 22 | 2 | 12 | 10 | 17 | 16 | 18 | 15 | ||||||
| Other Liabilities | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 32 | 23 | 17 | 23 | 22 | 2 | 120 | 10 | 17 | 16 | 18 | 15 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 711 | 512 | 507 | 322 | 319 | 311 | 0 | 308 | 306 | 278 | 273 | 269 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -271 | -215 | -174 | -142 | -117 | -236 | -47 | -228 | -211 | -187 | -163 | -143 | ||||||
| Stockholders Equity | 440 | 296 | 333 | 179 | 202 | -84 | -47 | -17 | -0 | 91 | 109 | 126 | ||||||
| Liabilities And Stockholders Equity | 472 | 319 | 350 | 202 | 224 | 78 | 73 | 91 | 112 | 107 | 127 | 141 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Series Seed Convertible Preferred Stock | - | - | 0 | 0 | -0 | 0 | 0 | 0 | 20 | - | - | - | ||||||
| Series A Non Voting Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Related Party | 0 | 0 | 0 | -2 | 2 | - | 0 | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | - | - | - | 13 | 13 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 150 | 40 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 64 | 49 | 49 | 33 | 33 | 29 | 4 | 29 | 29 | 28 | 28 | 28 | ||||||
| Shares Outstanding | 64 | 49 | 49 | 33 | 33 | 29 | 4 | 29 | 29 | 28 | 28 | 28 | ||||||
| Convertible Long Term Notes Payable | - | - | 0 | 0 | - | - | 108 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialJade Biosciences, Inc. (JBIO) — SEC Financial Statements & Analysis
Jade Biosciences, Inc. (JBIO) is a pharmaceutical preparations company, incorporated in DE. Jade Biosciences, Inc. trades on Nasdaq as: JBIO. Jade Biosciences, Inc. (JBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Jade Biosciences, Inc. carries a market cap of $1.36B, a P/E ratio of -8.85x, a P/B ratio of 3.08x, an enterprise value of $1.25B, and an EV/EBITDA multiple of -7.59x. On profitability, it posts a Return on Equity (ROE) of -47.78%, a Return on Assets (ROA) of -44.03%, and a Return on Invested Capital (ROIC) of -105.15%. Per share, it reports EPS of $-2.51, diluted EPS of $-2.51, free cash flow per share of $-2.03, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 63.88% year-over-year and EPS growth of -23.68% year-over-year. On the balance sheet, it maintains a current ratio of 14.93x, a quick ratio of 14.61x, working capital of $439.68M, a debt-to-equity ratio of 0.07x, a debt ratio of 0.07, an interest coverage ratio of -14.12x, free cash flow of $-123.71M (TTM), and net debt of $-107.25M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.36B
- P/E TTM
- -8.85x
- EPS TTM
- $-2.51
- P/B TTM
- 3.08x
- ROE TTM
- -47.78%
- ROA TTM
- -44.03%
- Debt To Equity
- 0.07x
- Free Cash Flow TTM
- $-123.71M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Jade Biosciences, Inc. in?
Jade Biosciences, Inc. (JBIO) operates in the Pharmaceutical Preparations industry.
What exchange does JBIO trade on?
Jade Biosciences, Inc. (JBIO) trades on the Nasdaq.
Where is Jade Biosciences, Inc. incorporated?
Jade Biosciences, Inc. is incorporated in DE.
When was Jade Biosciences, Inc. (JBIO)'s most recent SEC filing?
Jade Biosciences, Inc. (JBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is JBIO's market cap?
Jade Biosciences, Inc. (JBIO) has a market capitalization of $1.36B as of 2026-06-30.
What is JBIO's EPS (earnings per share)?
Jade Biosciences, Inc. (JBIO)'s trailing twelve month EPS is $-2.51 as of 2026-06-30.
What is JBIO's ROE (return on equity)?
Jade Biosciences, Inc. (JBIO)'s trailing twelve month Return on Equity (ROE) is -47.78% as of 2026-06-30.
What is JBIO's ROA (return on assets)?
Jade Biosciences, Inc. (JBIO)'s trailing twelve month Return on Assets (ROA) is -44.03% as of 2026-06-30.
What is JBIO's ROIC (return on invested capital)?
Jade Biosciences, Inc. (JBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -105.15% as of 2026-06-30.
What is JBIO's EV/EBITDA?
Jade Biosciences, Inc. (JBIO)'s trailing twelve month EV/EBITDA is -7.59x as of 2026-06-30.